ClinicalTrials.gg
CompletedNCT01201356Updated Apr 21, 2021Results posted

Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

A Phase 3 interventional study of Fingolimod in Relapsing Forms of Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 458 sites in 38 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-21.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,125
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.

Enrollment
2nd of 34
4,125 · median 167
Started
2010
with 3 others
Phase 3
12 of 34
1 open now
Registered
12th of 34
by date
Lead sponsor
20 of 34
Novartis Pharmaceuticals

Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 2nd largest by enrollment, is one of 4 that started in 2010, is one of 12 in phase 3, and was the 12th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing fingolimod in Multiple Sclerosis, or all of them as a file.
02

Study summary

The purpose of this study was to collect long-term safety and tolerability, long-term efficacy, and health outcome data in all patients currently ongoing in the fingolimod multiple sclerosis clinical development program. This study combined all currently ongoing Phase II and III fingolimod extension studies as well as ongoing and newly planned studies into one single long-term extension protocol that provided patients with continuous treatment until fingolimod was registered, commercially available, and reimbursed in the respective countries.

Read the detailed description

This study had two parts:

  • Part 1, collecting long-term safety, tolerability, efficacy and health outcomes data through approximately 30-Jun-2016 until all end of study (EOS) visits of Part 1 and last follow-up visit through Jan-2017 and
  • Part 2, collecting limited safety and tolerability data until approximately 30 Jun 2018, in a subset of patients who participated in Part 1, and other eligible patients from ongoing fingolimod trials.
03

Conditions studied

  • Relapsing Forms of Multiple Sclerosis

Browse trials for

Keywords

  • Fingolimod
  • FTY720
  • Relapsing forms of MS
  • Multiple Sclerosis
  • Efficacy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients who have completed selected ongoing or planned trials with FTY720.

Key Exclusion Criteria:

  • Premature permanent discontinuation of a previous fingolimod study.
  • Pregnant or nursing (lactating) women.
  • Women of , UNLESS they are using two methods, at least 1 of which must be hormonal contraception, tubal sterilization, partner's vasectomy or intrauterine device.
  • Chronic disease of the immune system, other than multiple sclerosis, which may require treatment.
  • Diabetic patients with moderate or severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy and uncontrolled diabetic patients with > 8%.
  • Active systemic bacterial, viral or fungal infections, or known to have AIDS, , infection or have positive antibody, Hepatitis B surface antigen or Hepatitis C antibody tests.
  • Previous treatment with cladribine, cyclophosphamide or mitoxantrone.
  • Treatment with immunoglobulins and/or monoclonal antibodies (including Natalizumab) in the past 3 months during the previous fingolimod study:
  • Any of the following cardiovascular conditions that have developed during the previous fingolimod study:

    • Myocardial infarction within the past 6 months prior to entry in the extension study or with current unstable ischemic heart disease;
    • Cardiac failure (Class III, according to Classification) or any severe cardiac disease as determined by the investigator;
    • Arrhythmia requiring current treatment with Class III antiarrhythmic drugs (e.g., amiodarone, bretylium, sotalol, ibutilide, azimilide, dofetilide)
    • History or presence of a third degree AV block
    • Proven history of sick sinus syndrome or sino-atrial heart block
    • Known history of angina pectoris due to coronary spasm or Raynaud's phenomenon
  • Any of the following pulmonary conditions during the previous fingolimod study:

    • Severe respiratory disease or pulmonary fibrosis diagnosed (during the previous fingolimod study)
    • Active tuberculosis
  • Alcohol abuse, chronic liver disease during the previous fingolimod study.

The patient must have participated in a previous fingolimod trial to be eligible to participate in this trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4,125 participants (actual)

Study arms

  • Experimental
    Fingolimod 0.5 mg/day

    Open-label fingolimod 0.5 mg, taken orally once daily

    Drug: Fingolimod

Interventions

06

What researchers measure

Primary outcomes

  1. Parts I and II: Number of Participants With Adverse Events, Serious Adverse Event, and Death

    Analysis of absolute and relative frequencies for Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) to demonstrate that Fingolimod 0.5 mg/day is safe in patients with relapsing forms of Multiple Sclerosis (MS) through the monitoring of relevant clinical and laboratory safety parameters. Only descriptive analysis performed.

    Time frame: Baseline (Part I) to Month 6 Follow-up (Part II), up to 8 years

Secondary outcomes

  1. Part I: Aggregate Annualized Relapse Rates (ARR) From First Dose of Fingolimod

    Annualized relapse rate (ARR) is defined as the number of all relapses (including both confirmed and unconfirmed relapses) experienced during a specific period of time adjusted to a one-year period. ARR is calculated as follows: (total number of all relapses) / (total number of days in the study for all patients for that specific period of time) x 365.25. Month 0 is the first dose of fingolimod study drug among all studies in which patient participated. Only descriptive analysis performed.

    Time frame: Month 0 (Core Baseline) to End of Follow-up Visit (an average of 162 months)

  2. Part I: Number of Participants With Relapses (Confirmed and Unconfirmed) From First Dose of Fingolimod

    A relapse is defined as the appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must be present for at least 24 hours and occur in the absence of fever (\<37.5°C) or infection. In Study Part One, a relapse must be confirmed by an Expanded Disability Status Scale (EDSS) certified Physician within 7 days of the onset of symptoms. A relapse is confirmed when it is accompanied by an increase of at least half a step (0.5) on the EDSS or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Month 0 is the first dose of fingolimod study drug among all studies in which patient participated. Only descriptive analysis performed.

    Time frame: Month 0 (Core Baseline) to End of Follow-up Visit (an average of 162 months)

  3. Part I: Annualized Rates of New or Newly Enlarging T2 Lesions (ARneT2) Compared With First Dose of Fingolimod

    Annualized rate of new/newly enlarging T2 lesions (ARneT2) is defined as the number of new or newly enlarging T2 lesions experienced during a specific period of time adjusted to a one-year period. ARneT2 was calculated as follows: (total number of new/newly enlarging T2 lesions) / (total number of days in the study for all patients for that specific period of time) x 365.25.Month 0 is the first dose of fingolimod study drug among all studies in which patient participated. Only descriptive analysis performed.

    Time frame: Month 0 (Core Baseline) to End of Study (an average of Month 156)

  4. Part I: Change From First Dose of Fingolimod in Total T2 Lesions Volume

    Total volume of T2 lesions was summarized by presenting descriptive statistics for change from first dose of fingolimod baseline values by visit.

    Time frame: Month 3 to End of Study (Study Completion Visit)

  5. Part I: Change From First Dose of Fingolimod in Total T1 Hypointense Lesions Volume

    T1 hypointense lesion (black hole) volume was summarized by presenting descriptive statistics for change from first dose of fingolimod baseline values by visit.

    Time frame: Month 3 to End of Study (Study Completion Visit)

  6. Part I: Percent Brain Volume Change (PBVC) Relative to First Dose of Fingolimod

    Descriptive statistics on percent brain volume change from first dose of fingolimod baseline were presented by visit. A negative change from baseline indicates improvement.

    Time frame: Month 3 to Month 156

  7. Part I: Annualized Rate of Brain Atrophy (ARBA) Relative to First Dose of Fingolimod

    The annualized rate of brain volume change is an "averaged annual percentage change" in brain volume. ARBA was calculated as: ARBA = \[(SIENA/100+1) \^ (365.25/#days)-1\]\*100 where SIENA=(Vk/V0-1)\*100 and Vk is the brain volume at time k, V0 is the brain volume at time 0 and k is the total number of days in the study for all patients for that specific period of time) × 365.25. Only descriptive analysis performed.

    Time frame: Month 3 to Month 156

  8. Part I: Number of Participants With Confirmed 6-month Disability Progression After First Dose of Fingolimod

    Disability progression was defined based on an increase in the EDSS score by 1.5 point for patients with a first dose of fingolimod (FDF) baseline EDSS score of 0, 1 point for patients with FDF baseline EDSS of \>=1 and \<=5.5, and by 0.5 points for patients with an FDF baseline EDSS\>5.5, confirmed after 6 months and all intermediate EDSS assessments. A 6-month confirmed disability progression was defined as a 6-month sustained increase from the reference (potential onset of progression) value in the EDSS scores. i.e., every EDSS score (scheduled or unscheduled) within a 6-month duration after the first progression should meet the progression criteria as specified above. The confirmation could only happen at a scheduled visit and in the absence of a relapse. Only descriptive analysis performed.

    Time frame: Month 12 to Month 156

  9. Part I: Number of Participants With Categorized Change From First Dose of Fingolimod in Expanded Disability Status Scale (EDSS) Overall Score

    The EDSS is a scale for assessing neurological impairment in MS (Kurtzke 1983) including (1) a series of scores in each of eight functional systems, and (2) the EDSS steps (ranging from 0 (normal) to 10 (death due to MS). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the participant's overall score is categorized as Improvement, Stable or Deterioration. If baseline EDSS score is \<=5, improvement is indicated by an EDSS score change of \<= -1, stable is indicated by an EDSS score change of \> -1 and \<= 0.5, deterioration is indicated by an EDSS score change of \> 0.5; if baseline EDSS score is \> 5, improvement is indicated by an EDSS score change of \<= -0.5, stable is indicated by an EDSS score change of \> -0.5 and \<= 0, deterioration is indicated by an EDSS score change of \> 0. Only descriptive analysis performed.

    Time frame: Month 3 to Month 6 Follow-up

  10. Part I: Change From First Dose of Fingolimod in Expanded Disability Status Scale (EDSS)

    The EDSS is a scale for assessing neurological impairment in MS (Kurtzke 1983) including (1) a series of scores in each of eight functional systems, and (2) the EDSS steps (ranging from 0 (normal) to 10 (death due to MS). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the participant's overall score is determined between 0 to 10. A negative change from baseline indicates improvement. Only descriptive analysis performed.

    Time frame: Month 0 (Core Baseline) to End of Follow-up Visit (an average of 162 months)

07

Results

Posted Nov 7, 2019

Participant flow

This was an open-label, multi-center, single treatment arm design allowing patients participating in the fingolimod MS clinical development program to enroll in order to collect additional long-term safety, tolerability, efficacy, and health outcomes data.

Participant flow — Overall Study
MilestoneFingolimod 0.5 mg/Day
Started4125
Safety set4083
Fingolimod full analysis set4046
Completed3481
Not completed644
Withdrew: Adverse event170
Withdrew: Abnormal laboratory value(s)51
Withdrew: Abnormal test procedure result(s)3
Withdrew: Unsatisfactory therapeutic effect112
Withdrew: Condition no longer requires study drug12
Withdrew: Withdrawal by subject144
Withdrew: Lost to follow-up50
Withdrew: Administrative problems74
Withdrew: Death16
Withdrew: Protocol violation12

Outcome measures

PrimaryParts I and II: Number of Participants With Adverse Events, Serious Adverse Event, and Death

Analysis of absolute and relative frequencies for Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) to demonstrate that Fingolimod 0.5 mg/day is safe in patients with relapsing forms of Multiple Sclerosis (MS) through the monitoring of relevant clinical and laboratory safety parameters. Only descriptive analysis performed.

Time frame:
Baseline (Part I) to Month 6 Follow-up (Part II), up to 8 years
Reported as:
Count of participants · Participants
Parts I and II: Number of Participants With Adverse Events, Serious Adverse Event, and Death
ParticipantsFingolimod 0.5 mg/Day
Adverse Event (AEs)2125
Serious Adverse Events (SAEs)515
Deaths16
SecondaryPart I: Aggregate Annualized Relapse Rates (ARR) From First Dose of Fingolimod

Annualized relapse rate (ARR) is defined as the number of all relapses (including both confirmed and unconfirmed relapses) experienced during a specific period of time adjusted to a one-year period. ARR is calculated as follows: (total number of all relapses) / (total number of days in the study for all patients for that specific period of time) x 365.25. Month 0 is the first dose of fingolimod study drug among all studies in which patient participated. Only descriptive analysis performed.

Time frame:
Month 0 (Core Baseline) to End of Follow-up Visit (an average of 162 months)
Reported as:
Number · Annual number of relapses per patient
Part I: Aggregate Annualized Relapse Rates (ARR) From First Dose of Fingolimod
Annual number of relapses per patientFingolimod 0.5 mg/Day
Month 0 to Month 60.325
Month 0 to Month 120.273
Month 0 to Month 240.237
Month 0 to Month 360.217
Month 0 to Month 480.208
Month 0 to Month 600.197
Month 0 to Month 720.190
Month 0 to Month 840.182
Month 0 to Month 960.177
Month 0 to Month 1080.172
Month 0 to Month 1200.170
Month 0 to Month 1320.170
Month 0 to Month 1440.169
Month 0 to Month 1560.169
Month 0 to end of Study0.166
Month 0 to end of Follow-up0.169
SecondaryPart I: Number of Participants With Relapses (Confirmed and Unconfirmed) From First Dose of Fingolimod

A relapse is defined as the appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must be present for at least 24 hours and occur in the absence of fever (\<37.5°C) or infection. In Study Part One, a relapse must be confirmed by an Expanded Disability Status Scale (EDSS) certified Physician within 7 days of the onset of symptoms. A relapse is confirmed when it is accompanied by an increase of at least half a step (0.5) on the EDSS or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Month 0 is the first dose of fingolimod study drug among all studies in which patient participated. Only descriptive analysis performed.

Time frame:
Month 0 (Core Baseline) to End of Follow-up Visit (an average of 162 months)
Reported as:
Number · Participants
Part I: Number of Participants With Relapses (Confirmed and Unconfirmed) From First Dose of Fingolimod
ParticipantsFingolimod 0.5 mg/Day
Month 0 to Month 6655
Month 0 to Month 12992
Month 0 to Month 241461
Month 0 to Month 361794
Month 0 to Month 482127
Month 0 to Month 602383
Month 0 to Month 722616
Month 0 to Month 842793
Month 0 to Month 962944
Month 0 to Month 1083036
Month 0 to Month 1203063
Month 0 to Month 1323072
Month 0 to Month 1443075
Month 0 to Month 1563079
Month 0 to end of Study2970
Month 0 to end of Follow-up3079
SecondaryPart I: Annualized Rates of New or Newly Enlarging T2 Lesions (ARneT2) Compared With First Dose of Fingolimod

Annualized rate of new/newly enlarging T2 lesions (ARneT2) is defined as the number of new or newly enlarging T2 lesions experienced during a specific period of time adjusted to a one-year period. ARneT2 was calculated as follows: (total number of new/newly enlarging T2 lesions) / (total number of days in the study for all patients for that specific period of time) x 365.25.Month 0 is the first dose of fingolimod study drug among all studies in which patient participated. Only descriptive analysis performed.

Time frame:
Month 0 (Core Baseline) to End of Study (an average of Month 156)
Reported as:
Number · Annual number of T2 lesions per patient
Part I: Annualized Rates of New or Newly Enlarging T2 Lesions (ARneT2) Compared With First Dose of Fingolimod
Annual number of T2 lesions per patientFingolimod 0.5 mg/Day
Month 0 to Month 312.324
Month 0 to Month 62.073
Month 0 to Month 121.360
Month 0 to Month 241.042
Month 0 to Month 361.011
Month 0 to Month 481.008
Month 0 to Month 600.957
Month 0 to Month 720.963
Month 0 to Month 840.906
Month 0 to Month 960.813
Month 0 to Month 1080.713
Month 0 to Month 1200.702
Month 0 to Month 1320.659
Month 0 to Month 1440.681
Month 0 to Month 1560.637
Month 0 to end of study0.751
SecondaryPart I: Change From First Dose of Fingolimod in Total T2 Lesions Volume

Total volume of T2 lesions was summarized by presenting descriptive statistics for change from first dose of fingolimod baseline values by visit.

Time frame:
Month 3 to End of Study (Study Completion Visit)
Reported as:
Mean · mm^3
Part I: Change From First Dose of Fingolimod in Total T2 Lesions Volume
mm^3Fingolimod 0.5 mg/Day
T2 volume change at Month 3-749.5 ± 5269.04
T2 volume change at Month 6-207.0 ± 1385.64
T2 volume change at Month 12-55.0 ± 1700.16
T2 volume change at Month 2416.2 ± 2009.87
T2 volume change at Month 36235.8 ± 2519.39
T2 volume change at Month 48875.1 ± 4145.99
T2 volume change at Month 601546.3 ± 4556.51
T2 volume change at Month 721719.2 ± 5184.27
T2 volume change at Month 841635.8 ± 5075.13
T2 volume change at Month 961303.9 ± 4712.78
T2 volume change at Month 1081562.0 ± 4654.67
T2 volume change at Month 1201393.1 ± 4908.76
T2 volume change at Month 132905.9 ± 3960.94
T2 volume change at Month 144702.7 ± 3765.80
T2 volume change at Month 156274.0 ± 5784.85
T2 volume change at End of Study1588.5 ± 5157.00
SecondaryPart I: Change From First Dose of Fingolimod in Total T1 Hypointense Lesions Volume

T1 hypointense lesion (black hole) volume was summarized by presenting descriptive statistics for change from first dose of fingolimod baseline values by visit.

Time frame:
Month 3 to End of Study (Study Completion Visit)
Reported as:
Mean · mm^3
Part I: Change From First Dose of Fingolimod in Total T1 Hypointense Lesions Volume
mm^3Fingolimod 0.5 mg/Day
T1 volume change at Month 3-519.8 ± 1339.62
T1 volume change at Month 1249.1 ± 718.77
T1 volume change at Month 2464.1 ± 786.02
T1 volume change at Month 36151.08 ± 1001.28
T1 volume change at Month 48524.8 ± 1706.26
T1 volume change at Month 60853.6 ± 1957.74
T1 volume change at Month 72975.7 ± 2637.67
T1 volume change at Month 84930.1 ± 2471.70
T1 volume change at Month 96753.4 ± 1845.63
T1 volume change at Month 108628.7 ± 1922.45
T1 volume change at Month 120817.3 ± 2198.58
T1 volume change at Month 132726.7 ± NA
T1 volume change at End of Study800.6 ± 2247.27
SecondaryPart I: Percent Brain Volume Change (PBVC) Relative to First Dose of Fingolimod

Descriptive statistics on percent brain volume change from first dose of fingolimod baseline were presented by visit. A negative change from baseline indicates improvement.

Time frame:
Month 3 to Month 156
Reported as:
Mean · Percent change
Part I: Percent Brain Volume Change (PBVC) Relative to First Dose of Fingolimod
Percent changeFingolimod 0.5 mg/Day
Percent volume change at Month 3-0.19 ± 0.660
Percent volume change at Month 6-0.20 ± 0.801
Percent volume change at Month 12-0.36 ± 0.901
Percent volume change at Month 24-0.74 ± 1.209
Percent volume change at Month 36-1.03 ± 1.541
Percent volume change at Month 48-1.44 ± 1.851
Percent volume change at Month 60-1.65 ± 2.196
Percent volume change at Month 72-2.02 ± 2.514
Percent volume change at Month 84-2.38 ± 2.638
Percent volume change at Month 96-2.41 ± 2.607
Percent volume change at Month 108-2.91 ± 2.863
Percent volume change at Month 120-3.42 ± 2.911
Percent volume change at Month 132-4.61 ± 2.511
Percent volume change at Month 144-4.21 ± 2.778
Percent volume change at Month 156-4.33 ± 3.146
SecondaryPart I: Annualized Rate of Brain Atrophy (ARBA) Relative to First Dose of Fingolimod

The annualized rate of brain volume change is an "averaged annual percentage change" in brain volume. ARBA was calculated as: ARBA = \[(SIENA/100+1) \^ (365.25/#days)-1\]\*100 where SIENA=(Vk/V0-1)\*100 and Vk is the brain volume at time k, V0 is the brain volume at time 0 and k is the total number of days in the study for all patients for that specific period of time) × 365.25. Only descriptive analysis performed.

Time frame:
Month 3 to Month 156
Reported as:
Mean · Ratio
Part I: Annualized Rate of Brain Atrophy (ARBA) Relative to First Dose of Fingolimod
RatioFingolimod 0.5 mg/Day
Month 3-0.73 ± 2.834
Month 6-0.39 ± 1.590
Month 12-0.35 ± 0.891
Month 24-0.37 ± 0.615
Month 36-0.35 ± 0.522
Month 48-0.37 ± 0.480
Month 60-0.34 ± 0.451
Month 72-0.35 ± 0.433
Month 84-0.35 ± 0.395
Month 96-0.31 ± 0.340
Month 108-0.33 ± 0.326
Month 120-0.36 ± 0.308
Month 132-0.43 ± 0.240
Month 144-0.36 ± 0.244
Month 156-0.35 ± 0.256
SecondaryPart I: Number of Participants With Confirmed 6-month Disability Progression After First Dose of Fingolimod

Disability progression was defined based on an increase in the EDSS score by 1.5 point for patients with a first dose of fingolimod (FDF) baseline EDSS score of 0, 1 point for patients with FDF baseline EDSS of \>=1 and \<=5.5, and by 0.5 points for patients with an FDF baseline EDSS\>5.5, confirmed after 6 months and all intermediate EDSS assessments. A 6-month confirmed disability progression was defined as a 6-month sustained increase from the reference (potential onset of progression) value in the EDSS scores. i.e., every EDSS score (scheduled or unscheduled) within a 6-month duration after the first progression should meet the progression criteria as specified above. The confirmation could only happen at a scheduled visit and in the absence of a relapse. Only descriptive analysis performed.

Time frame:
Month 12 to Month 156
Reported as:
Number · Participants
Part I: Number of Participants With Confirmed 6-month Disability Progression After First Dose of Fingolimod
ParticipantsFingolimod 0.5 mg/Day
Month 12212
Month 24336
Month 36434
Month 48519
Month 60590
Month 72659
Month 84714
Month 96753
Month 108767
Month 120772
Month 132775
Month 144776
Month 156777
SecondaryPart I: Number of Participants With Categorized Change From First Dose of Fingolimod in Expanded Disability Status Scale (EDSS) Overall Score

The EDSS is a scale for assessing neurological impairment in MS (Kurtzke 1983) including (1) a series of scores in each of eight functional systems, and (2) the EDSS steps (ranging from 0 (normal) to 10 (death due to MS). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the participant's overall score is categorized as Improvement, Stable or Deterioration. If baseline EDSS score is \<=5, improvement is indicated by an EDSS score change of \<= -1, stable is indicated by an EDSS score change of \> -1 and \<= 0.5, deterioration is indicated by an EDSS score change of \> 0.5; if baseline EDSS score is \> 5, improvement is indicated by an EDSS score change of \<= -0.5, stable is indicated by an EDSS score change of \> -0.5 and \<= 0, deterioration is indicated by an EDSS score change of \> 0. Only descriptive analysis performed.

Time frame:
Month 3 to Month 6 Follow-up
Reported as:
Count of participants · Participants
Part I: Number of Participants With Categorized Change From First Dose of Fingolimod in Expanded Disability Status Scale (EDSS) Overall Score
ParticipantsFingolimod 0.5 mg/Day
Month 3 — Improvement374
Month 3 — Stable3126
Month 3 — Deterioration269
Month 6 — Improvement508
Month 6 — Stable2900
Month 6 — Deterioration340
Month 9 — Improvement482
Month 9 — Stable2425
Month 9 — Deterioration304
Month 12 — Improvement422
Month 12 — Stable1930
Month 12 — Deterioration322
Month 15 — Improvement405
Month 15 — Stable1764
Month 15 — Deterioration285
Month 18 — Improvement345
Month 18 — Stable1361
Month 18 — Deterioration271
Month 21 — Improvement376
Month 21 — Stable1524
Month 21 — Deterioration287
Month 24 — Improvement320
Month 24 — Stable1299
Month 24 — Deterioration294
Month 27 — Improvement313
Month 27 — Stable1271
Month 27 — Deterioration270
Month 30 — Improvement305
Month 30 — Stable1204
Month 30 — Deterioration287
Month 33 — Improvement326
Month 33 — Stable1172
Month 33 — Deterioration292
Month 36 — Improvement309
Month 36 — Stable1065
Month 36 — Deterioration288
Month 39 — Improvement284
Month 39 — Stable1015
Month 39 — Deterioration276
Month 42 — Improvement282
Month 42 — Stable948
Month 42 — Deterioration287
Month 45 — Improvement244
Month 45 — Stable875
Month 45 — Deterioration263
Month 48 — Improvement250
Month 48 — Stable838
Month 48 — Deterioration264
Month 51 — Improvement244
Month 51 — Stable784
Month 51 — Deterioration247
Month 54 — Improvement256
Month 54 — Stable788
Month 54 — Deterioration251
Month 57 — Improvement201
Month 57 — Stable694
Month 57 — Deterioration245
Month 60 — Improvement175
Month 60 — Stable577
Month 60 — Deterioration234
Month 63 — Improvement182
Month 63 — Stable540
Month 63 — Deterioration191
Month 66 — Improvement165
Month 66 — Stable499
Month 66 — Deterioration216
Month 69 — Improvement156
Month 69 — Stable503
Month 69 — Deterioration193
Month 72 — Improvement143
Month 72 — Stable440
Month 72 — Deterioration206
Month 75 — Improvement156
Month 75 — Stable437
Month 75 — Deterioration201
Month 78 — Improvement136
Month 78 — Stable398
Month 78 — Deterioration226
Month 81 — Improvement150
Month 81 — Stable456
Month 81 — Deterioration217
Month 84 — Improvement132
Month 84 — Stable407
Month 84 — Deterioration207
Month 87 — Improvement147
Month 87 — Stable450
Month 87 — Deterioration227
Month 90 — Improvement120
Month 90 — Stable413
Month 90 — Deterioration204
Month 93 — Improvement143
Month 93 — Stable386
Month 93 — Deterioration187
Month 96 — Improvement117
Month 96 — Stable375
Month 96 — Deterioration186
Month 99 — Improvement110
Month 99 — Stable325
Month 99 — Deterioration159
Month 102 — Improvement94
Month 102 — Stable283
Month 102 — Deterioration154
Month 105 — Improvement103
Month 105 — Stable261
Month 105 — Deterioration131
Month 108 — Improvement87
Month 108 — Stable287
Month 108 — Deterioration138
Month 111 — Improvement74
Month 111 — Stable198
Month 111 — Deterioration101
Month 114 — Improvement45
Month 114 — Stable181
Month 114 — Deterioration79
Month 117 — Improvement31
Month 117 — Stable94
Month 117 — Deterioration52
Month 120 — Improvement19
Month 120 — Stable88
Month 120 — Deterioration42
Month 123 — Improvement9
Month 123 — Stable36
Month 123 — Deterioration21
Month 126 — Improvement14
Month 126 — Stable45
Month 126 — Deterioration26
Month 129 — Improvement6
Month 129 — Stable18
Month 129 — Deterioration12
Month 132 — Improvement11
Month 132 — Stable36
Month 132 — Deterioration21
Month 135 — Improvement5
Month 135 — Stable19
Month 135 — Deterioration12
Month 138 — Improvement10
Month 138 — Stable39
Month 138 — Deterioration18
Month 141 — Improvement6
Month 141 — Stable18
Month 141 — Deterioration12
Month 144 — Improvement7
Month 144 — Stable30
Month 144 — Deterioration19
Month 147 — Improvement6
Month 147 — Stable21
Month 147 — Deterioration15
Month 150 — Improvement7
Month 150 — Stable22
Month 150 — Deterioration15
Month 153 — Improvement8
Month 153 — Stable16
Month 153 — Deterioration8
Month 156 — Improvement3
Month 156 — Stable9
Month 156 — Deterioration5
Month 159 — Improvement1
Month 159 — Stable2
Month 159 — Deterioration6
Month 162 — Improvement0
Month 162 — Stable1
Month 162 — Deterioration1
End of study — Improvement610
End of study — Stable2419
End of study — Deterioration785
Month 3 follow-up — Improvement203
Month 3 follow-up — Stable907
Month 3 follow-up — Deterioration381
Month 6 follow-up — Improvement29
Month 6 follow-up — Stable111
Month 6 follow-up — Deterioration88
SecondaryPart I: Change From First Dose of Fingolimod in Expanded Disability Status Scale (EDSS)

The EDSS is a scale for assessing neurological impairment in MS (Kurtzke 1983) including (1) a series of scores in each of eight functional systems, and (2) the EDSS steps (ranging from 0 (normal) to 10 (death due to MS). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the participant's overall score is determined between 0 to 10. A negative change from baseline indicates improvement. Only descriptive analysis performed.

Time frame:
Month 0 (Core Baseline) to End of Follow-up Visit (an average of 162 months)
Reported as:
Mean · EDDS Overall Score
Part I: Change From First Dose of Fingolimod in Expanded Disability Status Scale (EDSS)
EDDS Overall ScoreFingolimod 0.5 mg/Day
Baseline (BL)2.39 ± 1.452
Change from BL at Month 3-0.06 ± 0.638
Change from BL at Month 6-0.07 ± 0.716
Change from BL at Month 9-0.09 ± 0.750
Change from BL at Month 12-0.07 ± 0.815
Change from BL at Month 15-0.08 ± 0.814
Change from BL at Month 18-0.05 ± 0.890
Change from BL at Month 21-0.08 ± 0.876
Change from BL at Month 24-0.01 ± 0.916
Change from BL at Month 27-0.03 ± 0.932
Change from BL at Month 30-0.00 ± 0.935
Change from BL at Month 33-0.02 ± 0.951
Change from BL at Month 360.01 ± 0.997
Change from BL at Month 390.02 ± 0.963
Change from BL at Month 420.04 ± 1.015
Change from BL at Month 450.06 ± 1.006
Change from BL at Month 480.06 ± 1.063
Change from BL at Month 510.06 ± 1.071
Change from BL at Month 540.04 ± 1.120
Change from BL at Month 570.09 ± 1.077
Change from BL at Month 600.17 ± 1.144
Change from BL at Month 630.08 ± 1.123
Change from BL at Month 660.15 ± 1.220
Change from BL at Month 690.14 ± 1.116
Change from BL at Month 720.22 ± 1.205
Change from BL at Month 750.13 ± 1.159
Change from BL at Month 780.28 ± 1.259
Change from BL at Month 810.18 ± 1.158
Change from BL at Month 840.25 ± 1.236
Change from BL at Month 870.24 ± 1.206
Change from BL at Month 900.29 ± 1.282
Change from BL at Month 930.18 ± 1.219
Change from BL at Month 960.31 ± 1.355
Change from BL at Month 990.18 ± 1.220
Change from BL at Month 1020.30 ± 1.332
Change from BL at Month 1050.21 ± 1.320
Change from BL at Month 1080.28 ± 1.270
Change from BL at Month 1110.24 ± 1.343
Change from BL at Month 1140.30 ± 1.258
Change from BL at Month 1170.35 ± 1.389
Change from BL at Month 1200.40 ± 1.271
Change from BL at Month 1230.60 ± 1.302
Change from BL at Month 1260.38 ± 1.441
Change from BL at Month 1290.40 ± 1.448
Change from BL at Month 1320.40 ± 1.450
Change from BL at Month 1350.51 ± 1.519
Change from BL at Month 1380.42 ± 1.527
Change from BL at Month 1410.54 ± 1.509
Change from BL at Month 1440.60 ± 1.553
Change from BL at Month 1470.67 ± 1.640
Change from BL at Month 1500.44 ± 1.483
Change from BL at Month 1530.23 ± 1.534
Change from BL at Month 1560.26 ± 1.427
Change from BL at Month 1591.17 ± 1.369
Change from BL at Month 1620.75 ± 1.061
Change from BL at End of study0.14 ± 1.108
Change from BL at Month 3 follow-up0.29 ± 1.248
Change from BL at Month 6 follow-up0.56 ± 1.487

Adverse events

Collected over Adverse events were collected from first dose of study treatment in Study Part I until end of study treatment in Study Part II plus 6 weeks post treatment, up to a maximum duration of 8 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fingolimod 0.5 mg/Day16/4,083 (0.4%)515/4,083 (12.6%)2,125/4,083 (52%)
Most frequent serious events
Showing 10 of 394
Most frequent serious events
EventFingolimod 0.5 mg/Day
Multiple sclerosis relapseNervous system disorders34/4083
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)30/4083
PneumoniaInfections and infestations14/4083
Urinary tract infectionInfections and infestations14/4083
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)11/4083
CholelithiasisHepatobiliary disorders10/4083
AppendicitisInfections and infestations10/4083
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)10/4083
Abortion spontaneousPregnancy, puerperium and perinatal conditions10/4083
Herpes zosterInfections and infestations9/4083
Most frequent other events
Showing 10 of 13
Most frequent other events
EventFingolimod 0.5 mg/Day
NasopharyngitisInfections and infestations706/4083
HeadacheNervous system disorders348/4083
Upper respiratory tract infectionInfections and infestations346/4083
Urinary tract infectionInfections and infestations335/4083
Back painMusculoskeletal and connective tissue disorders279/4083
InfluenzaInfections and infestations275/4083
HypertensionVascular disorders243/4083
FatigueGeneral disorders232/4083
LymphopeniaBlood and lymphatic system disorders219/4083
BronchitisInfections and infestations214/4083

Baseline characteristics

Participant Flow and Baseline Characteristics were based on the Enrolled set. Efficacy analyses were based on the Fingolimod Full Analysis Set..

Age, Continuous
Age, Continuous(years)Fingolimod 0.5 mg/Day
Mean37.8 ± 9.05
Age, Customized
Age, Customized(Participants)Fingolimod 0.5 mg/Day
< 18 years1
18 - 30 years951
31 - 40 years1497
41 - 55 years1605
> 55 years71
Sex: Female, Male
Sex: Female, Male(Participants)Fingolimod 0.5 mg/Day
Female2933
Male1192
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Fingolimod 0.5 mg/Day
Caucasian3927
Black38
Asian35
Native American11
Other114
08

Study locations

458 sites
  • Novartis Investigative Site
    Cullman, Alabama 35058, United States
  • Novartis Investigative Site
    Oceanside, California 92056, United States
  • Novartis Investigative Site
    Sacramento, California 95817, United States
  • Novartis Investigative Site
    San Francisco, California 94143, United States
  • Novartis Investigative Site
    Washington, District of Columbia 20007, United States
  • Novartis Investigative Site
    Jacksonville, Florida 32209, United States
  • Novartis Investigative Site
    Maitland, Florida 32751, United States
  • Novartis Investigative Site
    Miami, Florida 33136, United States
  • Novartis Investigative Site
    Sunrise, Florida 33351, United States
  • Novartis Investigative Site
    Tallahassee, Florida 32308, United States
  • Novartis Investigative Site
    Tampa, Florida 33609, United States
  • Novartis Investigative Site
    Vero Beach, Florida 32960, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30327, United States
  • Novartis Investigative Site
    Kansas City, Kansas 66160, United States
  • Novartis Investigative Site
    Lenexa, Kansas 66212, United States
  • Novartis Investigative Site
    Baltimore, Maryland 21201, United States
  • Novartis Investigative Site
    Baltimore, Maryland 21287, United States
  • Novartis Investigative Site
    Kansas City, Missouri 64111, United States
  • Novartis Investigative Site
    Lebanon, New Hampshire 03756, United States
  • Novartis Investigative Site
    Albuquerque, New Mexico 87131-0001, United States
  • Novartis Investigative Site
    New York, New York 10021, United States
  • Novartis Investigative Site
    Durham, North Carolina 27710, United States
  • Novartis Investigative Site
    Raleigh, North Carolina 27607, United States
  • Novartis Investigative Site
    Toledo, Ohio 43614, United States
  • Novartis Investigative Site
    Oklahoma City, Oklahoma 73104, United States
  • Novartis Investigative Site
    Tulsa, Oklahoma 74136, United States
  • Novartis Investigative Site
    Tualatin, Oregon 97062, United States
  • Novartis Investigative Site
    Pittsburgh, Pennsylvania 15213, United States
  • Novartis Investigative Site
    Bristol, Tennessee 37620, United States
  • Novartis Investigative Site
    Nashville, Tennessee 37212, United States
  • Novartis Investigative Site
    San Antonio, Texas 78229, United States
  • Novartis Investigative Site
    Burlington, Vermont 05401, United States
  • Novartis Investigative Site
    Charlottesville, Virginia 22904, United States
  • Novartis Investigative Site
    Seattle, Washington 98122, United States
  • Novartis Investigative Site
    Caba, Buenos Aires 1425, Argentina
  • Novartis Investigative Site
    Caba, Buenos Aires C1181ACH, Argentina
  • Novartis Investigative Site
    Caba, Buenos Aires C1428AQK, Argentina
  • Novartis Investigative Site
    Capital Federal, Buenos Aires C1192AAW, Argentina
  • Novartis Investigative Site
    Guaymallen, Mendoza M5507XAD, Argentina
  • Novartis Investigative Site
    Ciudad de Salta, Provincia De Salta A4406BPF, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe 2000, Argentina
  • Novartis Investigative Site
    San Miguel de Tucumán, Tucumán 4000, Argentina
  • Novartis Investigative Site
    Cordoba, X5004CDT, Argentina
  • Novartis Investigative Site
    Salta, A4400BKZ, Argentina
  • Novartis Investigative Site
    Camperdown, New South Wales 2050, Australia
  • Novartis Investigative Site
    Chatswood, New South Wales 2067, Australia
  • Novartis Investigative Site
    Kogarah, New South Wales 2217, Australia
  • Novartis Investigative Site
    Liverpool, New South Wales 2170, Australia
  • Novartis Investigative Site
    North Gosford, New South Wales 2250, Australia
  • Novartis Investigative Site
    Woodville, South Australia 5011, Australia
  • Novartis Investigative Site
    Box Hill, Victoria 3128, Australia
  • Novartis Investigative Site
    Fitzroy, Victoria 3065, Australia
  • Novartis Investigative Site
    Heidelberg, Victoria 3084, Australia
  • Novartis Investigative Site
    Parkville, Victoria 3050, Australia
  • Novartis Investigative Site
    Innsbruck, Tyrol 6020, Austria
  • Novartis Investigative Site
    Linz, A-4020, Austria
  • Novartis Investigative Site
    Salzburg, 5020, Austria
  • Novartis Investigative Site
    St Poelten, 3100, Austria
  • Novartis Investigative Site
    Vienna, 1010, Austria
  • Novartis Investigative Site
    Vienna, 1090, Austria
  • Novartis Investigative Site
    Aalst, 9300, Belgium
  • Novartis Investigative Site
    Brugge, 8000, Belgium
  • Novartis Investigative Site
    Brussel, 1090, Belgium
  • Novartis Investigative Site
    Bruxelles, 1070, Belgium
  • Novartis Investigative Site
    Bruxelles, 1200, Belgium
  • Novartis Investigative Site
    Charleroi, 6000, Belgium
  • Novartis Investigative Site
    Fraiture En Condroz, 4557, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Melsbroek, 1820, Belgium
  • Novartis Investigative Site
    Pelt, 3900, Belgium
  • Novartis Investigative Site
    Sijsele, 8340, Belgium
  • Novartis Investigative Site
    Sint-Truiden, 3800, Belgium
  • Novartis Investigative Site
    Wilrijk, 2610, Belgium
  • Novartis Investigative Site
    Porto Alegre, Rio Grande Do Sul 90610-000, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, RJ 20270-004, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, RJ 21941-913, Brazil
  • Novartis Investigative Site
    Rio De Janiero, RJ 20221-161, Brazil
  • Novartis Investigative Site
    Porto Alegre, RS 90020-090, Brazil
  • Novartis Investigative Site
    Campinas, SP 13083-970, Brazil
  • Novartis Investigative Site
    Ribeirao Preto, SP 14048-900, Brazil
  • Novartis Investigative Site
    Edmonton, Alberta T6G 2G3, Canada
  • Novartis Investigative Site
    Burnaby, British Columbia V5G 2X6, Canada
  • Novartis Investigative Site
    Vancouver, British Columbia V6T 1Z3, Canada
  • Novartis Investigative Site
    Victoria, British Columbia V8R 1J8, Canada
  • Novartis Investigative Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Novartis Investigative Site
    Kingston, Ontario K7L 2V7, Canada
  • Novartis Investigative Site
    London, Ontario N6A 5A5, Canada
  • Novartis Investigative Site
    Nepean, Ontario K2G 6E2, Canada
  • Novartis Investigative Site
    Ottawa, Ontario K1H 8L6, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5B 1W8, Canada
  • Novartis Investigative Site
    Greenfield Park, Quebec J4V 2J2, Canada
  • Novartis Investigative Site
    Montreal, Quebec H1T 2M4, Canada
  • Novartis Investigative Site
    Montreal, Quebec H2L 4M1, Canada
  • Novartis Investigative Site
    Montreal, Quebec H3A 2B4, Canada
  • Novartis Investigative Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Novartis Investigative Site
    Regina, Saskatchewan S4T 1A5, Canada
  • Novartis Investigative Site
    Quebec, G1J 1Z4, Canada
  • Novartis Investigative Site
    Brno, Czech Republic 656 91, Czechia
  • Novartis Investigative Site
    Olomouc, CZE 775 20, Czechia
  • Novartis Investigative Site
    Ostrava-Poruba, 708 00, Czechia

Showing the first 100 of 458 sites across 38 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cohen JA, Tenenbaum N, Bhatt A, Zhang Y, Kappos L. Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. Ther Adv Neurol Disord. 2019 Sep 25;12:1756286419878324. doi: 10.1177/1756286419878324. eCollection 2019. PubMed 31598139 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2010 to primary completion in Oct 2018, 97 months.

Results were first posted in Nov 2019, 1 year after primary completion.

Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 97 months is above that.

Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2010
First posted
Sep 14, 2010
StartActual
Sep 13, 2010
Primary completionActual
Oct 19, 2018
CompletionActual
Oct 19, 2018
Results first posted
Nov 7, 2019
Last update
Apr 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01201356
Responsible party
Sponsor
First posted
Sep 14, 2010
Start date
Sep 13, 2010
Primary completion
Oct 19, 2018
Completion
Oct 19, 2018
Results posted
Nov 7, 2019
Last update
Apr 21, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion